Pentoxifylline

Generic Name: Pentoxifylline

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈N_₄O_₃

CAS Number: 6493-05-6

Unique Ingredient Identifier: SD6QCT3TSU

Background: Pentoxifylline (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties of blood and also has both anti-oxidant and anti-inflammatory properties. Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated...

Indication: Pentoxifylline is indicated for the treatment of intermittent claudication in patients with chronic occlusive arterial disease. Pentoxifylline may improve limb function and reduce symptoms but cannot replace other therapies such as surgical bypass or removal of vascular obstructions.

Associated Conditions: Intermittent Claudication, Venous Leg Ulcer (VLU), Severe alcoholic liver disease

Associated Therapies: -

Clinical Trials

Effects of Pentoxiphylline on Left Ventricular (LV) Systolic Function Indices and Circulating Biomarkers in Patients With Chronic Congestive Heart Failure (CHF)

Not Applicable

Withdrawn

Conditions: Congestive Heart Failure

Interventions: Drug: Placebo
Drug: Pentoxifylline

First Posted Date: 2011-04-18

Last Posted Date: 2022-08-01

Lead Sponsor: Henry Ford Health System

Registration Number: NCT01337349

Locations: 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States

Pentoxifylline Treatment of Acute Pancreatitis

Early Phase 1

Completed

Conditions: Acute Pancreatitis

Interventions: Drug: Placebo
Drug: Pentoxifylline

First Posted Date: 2011-02-09

Last Posted Date: 2016-10-25

Lead Sponsor: Mayo Clinic

Target Recruit Count: 28

Registration Number: NCT01292005

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Trial of Combined Pentoxifylline-tocopherol-clodronate vs Placebo in Radiation-induced Brachial Plexopathy

Phase 3

Completed

Conditions: Radiation Induced Brachial Plexopathy

Interventions: Drug: Pentoxifylline placebo
Drug: Pentoxifylline
Drug: Tocopherol placebo
Drug: Tocopherol acetate
Drug: Clodronic Acid
Drug: Clodronate placebo

First Posted Date: 2011-02-08

Last Posted Date: 2017-12-08

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 59

Registration Number: NCT01291433

Locations: 🇫🇷
Hôpital Saint-Louis, Paris, France
🇫🇷
Groupe Hospitalier Pitié-Salpêtrière, Paris, France

Pentoxifylline and Systemic Inflammation in Hemodialysis Patients

Phase 4

Completed

Conditions: Inflammation
End-stage Renal Disease
Hemodialysis

Interventions: Drug: Pentoxifylline
Drug: starch tablets

First Posted Date: 2011-01-04

Last Posted Date: 2018-12-19

Lead Sponsor: Coordinación de Investigación en Salud, Mexico

Target Recruit Count: 36

Registration Number: NCT01269827

Locations: 🇲🇽
Hospital de Especialidades, CMNO, IMSS, Guadalajara, Jalisco, Mexico

Prostaglandin E1 in Outpatients With Intermittent Claudication

Phase 3

Completed

Conditions: Stage II Peripheral Arterial Occlusive Disease
Intermittent Claudication Fontaine Stage II PAOD

Interventions: Drug: Alprostadil (Prostaglandin E1)
Drug: Pentoxifylline
Drug: Placebo to Pentoxifylline oral
Drug: Placebo to Alprostadil (Prostaglandin E1) intravenous

First Posted Date: 2010-12-21

Last Posted Date: 2014-10-27

Lead Sponsor: UCB Pharma

Target Recruit Count: 561

Registration Number: NCT01263925

Pentoxifylline for Primary Biliary Cirrhosis

Phase 2

Completed

Conditions: Primary Biliary Cirrhosis

Interventions: Drug: Pentoxifylline

First Posted Date: 2010-11-29

Last Posted Date: 2013-12-09

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 20

Registration Number: NCT01249092

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

Double-blind Randomized Controlled Trial in Severe Alcoholic Hepatitis

Phase 3

Completed

Conditions: Alcoholic Hepatitis
Alcoholic Liver Disease

Interventions: Drug: placebo
Drug: Pentoxifylline

First Posted Date: 2010-10-04

Last Posted Date: 2011-06-01

Lead Sponsor: University Hospital, Lille

Target Recruit Count: 278

Registration Number: NCT01214226

Locations: 🇫🇷
University hospital, Rennes, France
🇫🇷
Hôpital Jean Verdier (AH-HP), Bondy, France
🇫🇷
Centre hospitalier, Dunkerque, France

and more 12 locations

Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity

Phase 2

Completed

Conditions: Irradiation Damage
Liver Metastases
Radiation Induced Liver Disease
Colorectal Cancer

Interventions: Drug: Pentoxifylline
Drug: Ursodeoxycholic Acid
Drug: Enoxaparin

First Posted Date: 2010-06-23

Last Posted Date: 2017-11-20

Lead Sponsor: University of Magdeburg

Target Recruit Count: 22

Registration Number: NCT01149304

Locations: 🇩🇪
Clinic for Radiology and Nuclear Medicine, Magdeburg, Sachsen-Anhalt, Germany

A Safety Study of Pentoxifylline for the Treatment of Anemia

Phase 2

Terminated

Conditions: End Stage Renal Disease

Interventions: Drug: Erythropoietin
Drug: Pentoxifylline

First Posted Date: 2010-04-13

Last Posted Date: 2012-03-28

Lead Sponsor: Fresenius Medical Care North America

Target Recruit Count: 48

Registration Number: NCT01102218

Locations: 🇺🇸
Fresenius Medical Care North America, Tyler, Texas, United States

Prevention of Capsular Contracture Using Trental and Vitamin E

Not Applicable

Conditions: Capsular Contractures

Interventions: Drug: Trental

First Posted Date: 2010-03-05

Last Posted Date: 2013-08-28

Lead Sponsor: Legacy Health System

Target Recruit Count: 30

Registration Number: NCT01082003

Locations: 🇺🇸
Legacy Good Samaritan Medical Center, Portland, Oregon, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy